Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Everolimus in Comparison to Standard Therapy With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Cyclosporine Microemulsion in de Novo Renal Transplant Patients

Trial Profile

Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Everolimus in Comparison to Standard Therapy With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Cyclosporine Microemulsion in de Novo Renal Transplant Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms ZEUS
  • Sponsors Novartis
  • Most Recent Events

    • 11 Sep 2013 Results at 5 years follow-up presented at the 16th Congress of the European Society for Organ Transplantation.
    • 19 May 2013 Results of a 60-month follow-up analysis presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 07 Sep 2011 36-month follow-up results presented at the 15th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top